

Not for distribution or release in the United States or to U.S. persons

ASX Announcement

29th December 2023

GENETIC SIGNATURES SUCCESSFULLY COMPLETES PLACEMENT

Genetic Signatures Limited (ASX:GSS), an Australian-based global molecular diagnostics company (**Genetic Signatures** or the **Company**), is pleased to announce the successful completion of the placement (**Placement**) to new and existing sophisticated and professional investors of 21,510,899 new fully paid ordinary shares in the Company (**New Shares**), details of which were announced to ASX on Thursday, 21 December 2023. The Placement raised gross proceeds of approximately \$8 million at an offer price of \$0.37 per New Share.

On 21 December 2023, the Company also announced a fully underwritten pro-rata non-renounceable entitlement offer of 1 New Share for every 6.65 existing fully paid ordinary shares in the Company (**Shares**) held by eligible shareholders at the Record Date (being 7.00pm (Sydney time) on Thursday 28 December 2023) to raise a further approximately \$8 million and result in the issue of approximately 21.6 million New Shares (**Rights Issue**) at the same issue price of \$0.37 per share. The Rights Issue will be open from Tuesday, 2 January 2024 to 5.00pm (Sydney time) on Thursday, 18 January 2024 to Eligible Shareholders. Further details about the Rights Issue will be set out in the Offer Booklet, which Genetic Signatures expects to lodge with ASX and dispatch to eligible shareholders on Tuesday, 2 January 2024.

Under the Placement and Rights Issue (**Capital Raising**), the Company will result in total proceeds of approximately \$15.9 million before costs. Funds raised under the Capital Raising will be used for additional regulatory approvals, new customer installations, next generation Instrument development and new product development, general working capital and the costs of the Capital Raising.

Bell Potter Securities Limited and Taylor Collison Limited (**Joint Lead Managers** or the **Underwriters**) are acting as joint lead managers to the Capital Raising and underwriters to the Rights Issue pursuant to a lead mandate letter and underwriting agreement.

– ENDS –

Authorisation and Additional Information

This announcement was authorised by the Board of Directors of Genetic Signatures Limited.

For further information, see our website (www.geneticsignatures.com) or contact us as below:

Dr John Melki
Managing Director and
Chief Executive Officer
john.melki@geneticsignatures.com
T: +61 (0)2 9870 7580

Karl Pechmann
Chief Financial and Operating Officer
and Company Secretary
karl.pechmann@geneticsignatures.com

About Genetic Signatures Limited: Genetic Signatures is a specialist molecular diagnostics (MDx) company focused on the development and commercialisation of its proprietary platform technology, **3base®**. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the *EasyScreen™* brand. Genetic Signatures' proprietary MDx **3base®** platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospitals and pathology laboratories undertaking infectious disease screening. Genetic Signatures is leveraging strong COVID-19 related sales of its *EasyScreen™* respiratory kits and the growing interest in its gastroenteritis products to further commercialise its **3base®** technology to rapidly and cost effectively screen for a wide array of infectious pathogens including antibiotic resistant bacteria, sexually transmitted infections, meningitis and mosquito borne viral diseases.